Sex-related differences in time-to-onset of immune checkpoint inhibitor-related interstitial lung disease: a JADER pharmacovigilance study

Immune checkpoint inhibitors (ICIs) are widely used to treat malignancies, but may cause clinically important immune-related adverse events, including interstitial lung disease (ILD). The present study clarified the reporting patterns and reported time-to-onset of suspected ICI-related ILD using the Japanese Adverse Drug Event Report database. Reports from April 2004 to March 2026 were analyzed. Disproportionality signals based on both reporting odds ratio and information component were detected for all evaluated ICIs, except cemiplimab. The median reported time-to-onset was within approximately 2-3 months for the main analyzable ICIs, and Weibull shape parameters indicated early failure patterns for most ICIs. After adjustments for age category, pre-existing ILD, and indication category, male sex was associated with a shorter reported time-to-onset for nivolumab, but not for the other ICIs analyzed. These results suggest that sex-related differences in reported time-to-onset may be present in suspected nivolumab-related ILD reports.

Authors

Institutions

Publication Details

Journal
Journal of Chemotherapy
Published
2026-11-17
DOI
https://doi.org/10.1080/1120009x.2026.2763196
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Sex-related differences in time-to-onset of immune checkpoint inhibitor-related interstitial lung disease: a JADER pharmacovigilance study

竜助 渡辺, Tomoji Maeda, Ken-ichi Sako, Naohito Ide et al.
Journal of Chemotherapy
Cancer Immunotherapy and Biomarkers
article

Sex-related differences in time-to-onset of immune checkpoint inhibitor-related interstitial lung disease: a JADER pharmacovigilance study

竜助 渡辺, Tomoji Maeda, Ken-ichi Sako, Naohito Ide, Rin Yagome, Minori Yamashita, Chika Moriya, Miyako Yamashita
article en

Abstract

Immune checkpoint inhibitors (ICIs) are widely used to treat malignancies, but may cause clinically important immune-related adverse events, including interstitial lung disease (ILD). The present study clarified the reporting patterns and reported time-to-onset of suspected ICI-related ILD using the Japanese Adverse Drug Event Report database. Reports from April 2004 to March 2026 were analyzed. Disproportionality signals based on both reporting odds ratio and information component were detected for all evaluated ICIs, except cemiplimab. The median reported time-to-onset was within approximately 2-3 months for the main analyzable ICIs, and Weibull shape parameters indicated early failure patterns for most ICIs. After adjustments for age category, pre-existing ILD, and indication category, male sex was associated with a shorter reported time-to-onset for nivolumab, but not for the other ICIs analyzed. These results suggest that sex-related differences in reported time-to-onset may be present in suspected nivolumab-related ILD reports.

Journal of Chemotherapy
Nihon Pharmaceutical University (JP)
Cancer Immunotherapy and Biomarkers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon